|
ITRM20030601A1
(it)
*
|
2003-12-24 |
2005-06-25 |
Lay Line Genomics Spa |
Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
ITRM20050290A1
(it)
*
|
2005-06-07 |
2006-12-08 |
Lay Line Genomics Spa |
Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
|
|
EP4793360A2
(en)
|
2006-03-31 |
2026-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
|
JP5144499B2
(ja)
|
2006-03-31 |
2013-02-13 |
中外製薬株式会社 |
二重特異性抗体を精製するための抗体改変方法
|
|
ATE537190T1
(de)
|
2006-06-02 |
2011-12-15 |
Regeneron Pharma |
Hochaffine antikörper gegen den humanen il-6- rezeptor
|
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
|
EP2626372B1
(en)
|
2007-03-29 |
2018-03-21 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
EP2615175B1
(en)
*
|
2007-05-31 |
2018-08-08 |
Genmab A/S |
Monovalent human antibodies
|
|
EP3127921A1
(en)
|
2007-09-26 |
2017-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substition in cdr
|
|
ES2687808T3
(es)
|
2007-09-26 |
2018-10-29 |
Chugai Seiyaku Kabushiki Kaisha |
Región constante de anticuerpo modificado
|
|
US20110086366A1
(en)
*
|
2008-02-22 |
2011-04-14 |
Genmab A/S |
Methods for assessing the risk of adverse events upon treatment with igg4 antibodies
|
|
CA2745439C
(en)
|
2008-12-03 |
2019-10-15 |
Genmab A/S |
Antibody variants having modifications in the constant region
|
|
JP2012515556A
(ja)
*
|
2009-01-23 |
2012-07-12 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
|
|
TWI544077B
(zh)
|
2009-03-19 |
2016-08-01 |
中外製藥股份有限公司 |
Antibody constant region change body
|
|
ES2514319T3
(es)
|
2009-05-04 |
2014-10-28 |
Abbvie Research B.V. |
Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
|
NZ601580A
(en)
*
|
2010-02-11 |
2014-11-28 |
Alexion Pharma Inc |
Therapeutic methods using anti-cd200 antibodies
|
|
CA2791652C
(en)
|
2010-03-02 |
2018-06-12 |
Kyowa Kirin Co., Ltd. |
Modified antibody composition
|
|
EP2543730B1
(en)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
EP3904391B1
(en)
|
2010-03-10 |
2024-07-10 |
Genmab A/S |
Monoclonal antibodies against c-met
|
|
KR20130031247A
(ko)
|
2010-03-17 |
2013-03-28 |
애보트 리서치 비.브이. |
항―신경 성장 인자（ｎｇｆ） 항체 조성물
|
|
PT2560993T
(pt)
*
|
2010-04-20 |
2024-09-16 |
Genmab As |
Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
|
|
US9352000B2
(en)
|
2010-05-05 |
2016-05-31 |
Rappaport Family Institute For Research In The Medical Sciences |
Use of CCL1 in therapy
|
|
US9717777B2
(en)
|
2010-05-05 |
2017-08-01 |
Rappaport Family Institute For Research In The Medical Sciences |
Use of CCL1 in therapy
|
|
IL299365A
(en)
|
2010-05-27 |
2023-02-01 |
Genmab As |
Monoclonal antibodies against 2HER
|
|
NZ604007A
(en)
|
2010-05-27 |
2015-03-27 |
Genmab As |
Monoclonal antibodies against her2 epitope
|
|
JP6055404B2
(ja)
|
2010-06-15 |
2016-12-27 |
ゲンマブ エー／エス |
組織因子に対するヒト抗体薬物結合体
|
|
EP2598530A2
(en)
|
2010-07-29 |
2013-06-05 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
|
CN105859889B
(zh)
|
2010-11-17 |
2020-01-07 |
中外制药株式会社 |
具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
|
|
US9783601B2
(en)
|
2010-12-01 |
2017-10-10 |
Alderbio Holdings Llc |
Methods of preventing inflammation and treating pain using anti-NGF compositions
|
|
US9067988B2
(en)
|
2010-12-01 |
2015-06-30 |
Alderbio Holdings Llc |
Methods of preventing or treating pain using anti-NGF antibodies
|
|
US9884909B2
(en)
|
2010-12-01 |
2018-02-06 |
Alderbio Holdings Llc |
Anti-NGF compositions and use thereof
|
|
US11214610B2
(en)
|
2010-12-01 |
2022-01-04 |
H. Lundbeck A/S |
High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
|
|
US9078878B2
(en)
|
2010-12-01 |
2015-07-14 |
Alderbio Holdings Llc |
Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
|
|
US9539324B2
(en)
|
2010-12-01 |
2017-01-10 |
Alderbio Holdings, Llc |
Methods of preventing inflammation and treating pain using anti-NGF compositions
|
|
WO2012125850A1
(en)
|
2011-03-16 |
2012-09-20 |
Amgen Inc. |
Fc variants
|
|
WO2012143524A2
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
|
CA2832387A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
EP2699260B1
(en)
|
2011-04-20 |
2024-11-20 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
EP2718325A4
(en)
*
|
2011-06-13 |
2015-03-11 |
ABGENOMICS COöPERATIEF U A |
ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
SI2766397T1
(sl)
|
2011-10-11 |
2018-09-28 |
F. Hoffmann-La Roche Ag |
Izboljšano sestavljanje bispecifičnih protiteles
|
|
TWI589299B
(zh)
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
|
IN2014CN03887A
(enExample)
|
2011-10-27 |
2015-10-16 |
Genmab As |
|
|
BR112014010257A2
(pt)
|
2011-10-31 |
2017-04-18 |
Chugai Pharmaceutical Co Ltd |
molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves
|
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
JO3820B1
(ar)
*
|
2012-05-03 |
2021-01-31 |
Regeneron Pharma |
أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
KR102391731B1
(ko)
|
2013-01-14 |
2022-04-27 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
BR112015018438A2
(pt)
*
|
2013-01-31 |
2017-07-18 |
Seoul Nat Univ R&Db Foundation |
anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
|
|
TWI682941B
(zh)
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
CN103193882B
(zh)
*
|
2013-03-29 |
2014-11-05 |
浙江大学 |
胚胎干细胞特异性标志物GM-CSFRα及其应用
|
|
EP3036543B1
(en)
|
2013-08-23 |
2019-06-19 |
Regeneron Pharmaceuticals, Inc. |
Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
|
|
SMT202300039T1
(it)
|
2013-09-13 |
2023-03-17 |
Beigene Switzerland Gmbh |
Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
|
|
CA2925256C
(en)
|
2013-09-27 |
2023-08-15 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
|
CR20160319A
(es)
|
2013-12-12 |
2016-11-08 |
Jiangsu Hengrui Medicine Co |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
|
|
JP6825909B2
(ja)
|
2014-02-28 |
2021-02-03 |
アラコス インコーポレイテッド |
シグレック−８関連疾患を処置するための方法および組成物
|
|
KR20200029627A
(ko)
*
|
2014-03-12 |
2020-03-18 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
|
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
PL3122781T3
(pl)
|
2014-03-28 |
2020-06-15 |
Xencor, Inc. |
Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
|
|
US10647768B2
(en)
|
2014-05-29 |
2020-05-12 |
Macrogenics, Inc. |
Multi-chain polypeptide-containing tri-specific binding molecules
|
|
CN106456734A
(zh)
*
|
2014-05-29 |
2017-02-22 |
免疫医疗有限责任公司 |
Ox40l融合蛋白及其用途
|
|
US20170211876A1
(en)
*
|
2014-06-12 |
2017-07-27 |
Hoffmann-La Roche Inc. |
Method for selecting antibodies with modified fcrn interaction
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
KR102524920B1
(ko)
|
2014-07-22 |
2023-04-25 |
아폴로믹스 인코포레이티드 |
항-pd-1 항체
|
|
SG10201901057UA
(en)
|
2014-08-05 |
2019-03-28 |
Cb Therapeutics Inc |
Anti-pd-l1 antibodies
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
TWI566780B
(zh)
*
|
2014-10-24 |
2017-01-21 |
國立陽明大學 |
巨噬細胞發炎蛋白－１β（ＭＩＰ－１β）抑制劑用於促進血管新生以改善組織缺血及糖尿病血管病變的用途
|
|
ES2809455T3
(es)
|
2014-11-17 |
2021-03-04 |
Regeneron Pharma |
Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
|
|
JP6696982B2
(ja)
|
2014-11-26 |
2020-05-20 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
HK1245171A1
(zh)
|
2014-11-26 |
2018-08-24 |
Xencor, Inc. |
结合cd3和cd38的异二聚体抗体
|
|
EP3229836B1
(en)
|
2014-12-09 |
2019-11-13 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Human monoclonal antibodies against axl
|
|
EP3233907B1
(en)
|
2014-12-19 |
2021-03-03 |
Genmab A/S |
Rodent bispecific heterodimeric proteins
|
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
CN107250161A
(zh)
|
2015-01-26 |
2017-10-13 |
宏观基因有限公司 |
包含dr5‑结合结构域的多价分子
|
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
DK3277725T3
(da)
|
2015-03-30 |
2021-01-11 |
Regeneron Pharma |
Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
|
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
EP3303380B1
(en)
|
2015-06-02 |
2020-01-15 |
Novo Nordisk A/S |
Insulins with polar recombinant extensions
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
TWI870335B
(zh)
|
2015-06-12 |
2025-01-21 |
美商宏觀基因股份有限公司 |
變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
|
|
HK1254432A1
(zh)
*
|
2015-06-17 |
2019-07-19 |
Allakos Inc. |
用於治疗纤维性疾病的方法和组合物
|
|
PE20231958A1
(es)
|
2015-07-30 |
2023-12-06 |
Macrogenics Inc |
Moleculas de union a pd-1 y metodos de uso de las mismas
|
|
MY195059A
(en)
|
2015-09-23 |
2023-01-05 |
Regeneron Pharma |
Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
|
|
BR112018006237A2
(pt)
|
2015-09-29 |
2018-10-09 |
Celgene Corp |
proteínas de ligação a pd-1 e métodos de uso das mesmas
|
|
WO2017055582A1
(en)
|
2015-10-01 |
2017-04-06 |
Novo Nordisk A/S |
Protein conjugates
|
|
UA128469C2
(uk)
|
2015-10-08 |
2024-07-24 |
Макродженікс, Інк. |
Спосіб лікування в7-н3-експресуючого раку
|
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
|
EP3387013B1
(en)
|
2015-12-07 |
2022-06-08 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
|
CN108367069B
(zh)
|
2015-12-14 |
2022-08-23 |
宏观基因有限公司 |
对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
|
|
SG11201803989WA
(en)
|
2015-12-28 |
2018-06-28 |
Chugai Pharmaceutical Co Ltd |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
|
CA3013333A1
(en)
|
2016-02-26 |
2017-08-31 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies having specificity for btla and uses thereof
|
|
EP3431102A4
(en)
|
2016-03-14 |
2019-09-25 |
Chugai Seiyaku Kabushiki Kaisha |
CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
|
|
KR102438140B1
(ko)
|
2016-03-22 |
2022-08-31 |
엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 |
인간화 항-클라우딘-1 항체 및 이의 용도
|
|
WO2017176525A1
(en)
*
|
2016-04-04 |
2017-10-12 |
Promab Biotechnologies, Inc. |
Car having replicated binding motifs in a co-stimulatory domain
|
|
AU2017255077B2
(en)
|
2016-04-28 |
2024-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing preparation
|
|
US11376269B2
(en)
|
2016-05-06 |
2022-07-05 |
Inserm |
Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (AML)
|
|
CA3025162A1
(en)
|
2016-05-26 |
2017-11-30 |
Qilu Puget Sound Biotherapeutics Corporation |
Mixtures of antibodies
|
|
CA3026151A1
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
RU2019102008A
(ru)
|
2016-06-28 |
2020-07-28 |
Ксенкор, Инк. |
Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
|
|
WO2018007885A1
(en)
|
2016-07-05 |
2018-01-11 |
Beigene, Ltd. |
COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
|
|
CN110087680B
(zh)
|
2016-08-19 |
2024-03-19 |
百济神州有限公司 |
使用包含btk抑制剂的组合产品治疗癌症
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
EP3515943A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
|
|
EP3515944A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHOD FOR TREATING IMMUNE DISEASES USING PD-1 BINDING PROTEINS
|
|
MX2019004327A
(es)
|
2016-10-14 |
2019-10-14 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
|
|
PL3558347T3
(pl)
|
2016-12-22 |
2026-04-20 |
Regeneron Pharmaceuticals, Inc. |
Sposób leczenia alergii swoistymi dla alergenu przeciwciałami monoklonalnymi
|
|
AR110755A1
(es)
|
2017-01-20 |
2019-05-02 |
Genzyme Corp |
Anticuerpos dirigidos a hueso
|
|
TW202506185A
(zh)
|
2017-01-20 |
2025-02-16 |
法商賽諾菲公司 |
抗TGF-β抗體及其用途
|
|
GB201701194D0
(en)
|
2017-01-24 |
2017-03-08 |
Capella Bioscience Ltd |
Antigen binding molecules that bind light
|
|
EP3573989A4
(en)
|
2017-01-25 |
2020-11-18 |
Beigene, Ltd. |
CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
|
|
WO2018166461A1
(en)
*
|
2017-03-14 |
2018-09-20 |
Sunshine Lake Pharma Co., Ltd. |
Dual-target fusion proteins comprising the fc portion of an immunoglobulin
|
|
JP7209298B2
(ja)
|
2017-03-31 |
2023-01-20 |
公立大学法人奈良県立医科大学 |
血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物
|
|
JP2020513019A
(ja)
|
2017-04-05 |
2020-04-30 |
ノヴォ ノルディスク アー／エス |
オリゴマー伸長インスリン−Ｆｃコンジュゲート
|
|
CN110709417B
(zh)
|
2017-04-07 |
2023-10-31 |
美天施生物科技有限责任两合公司 |
具有突变人IgG4的多肽
|
|
MX2019013136A
(es)
*
|
2017-05-05 |
2020-07-14 |
Allakos Inc |
Metodos y composiciones para tratar trastornos gastrointestinales inflamatorios.
|
|
BR112019022912A2
(pt)
|
2017-05-05 |
2020-05-26 |
Allakos Inc. |
Métodos e composições para tratar doenças oculares alérgicas
|
|
EP3645569A4
(en)
|
2017-06-26 |
2021-03-24 |
BeiGene, Ltd. |
IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
RU2646807C1
(ru)
*
|
2017-08-08 |
2018-03-07 |
Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" |
Способ выделения аутоантител подклассов иммуноглобулина G к иммунорегуляторному цитокину фактору некроза опухоли
|
|
KR102764182B1
(ko)
|
2017-09-21 |
2025-02-07 |
임체크 테라퓨틱스 |
Ｂｔｎ２에 대해 특이성을 갖는 항체 및 이의 용도
|
|
KR20260090008A
(ko)
|
2017-11-01 |
2026-06-16 |
추가이 세이야쿠 가부시키가이샤 |
생물 활성이 저하된 항체 배리언트 및 아이소폼
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
US11786529B2
(en)
|
2017-11-29 |
2023-10-17 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
|
|
JP7765181B2
(ja)
|
2017-12-19 |
2025-11-06 |
ゼンコア インコーポレイテッド |
改変されたｉｌ－２ ｆｃ融合タンパク質
|
|
US11312781B2
(en)
|
2018-01-24 |
2022-04-26 |
Capella Bioscience Ltd. |
Antigen binding molecules that bind LIGHT
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
WO2019204646A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
|
|
KR20210003814A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
|
|
CA3097625A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
|
ES3009025T3
(en)
|
2018-08-31 |
2025-03-25 |
Regeneron Pharma |
Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
|
|
JP6800191B2
(ja)
*
|
2018-09-21 |
2020-12-16 |
ベイジーン スウィッツァーランド ゲーエムベーハー |
抗ｐｄ−１抗体並びにその治療及び診断のための使用
|
|
KR102884523B1
(ko)
|
2018-10-03 |
2025-11-10 |
젠코어 인코포레이티드 |
IL-12 이종이량체 Fc-융합 단백질
|
|
CA3116188A1
(en)
|
2018-10-12 |
2020-04-16 |
Xencor, Inc. |
Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
|
|
TWI874341B
(zh)
|
2018-12-18 |
2025-03-01 |
美商健生生物科技公司 |
產生異二聚體抗體之方法
|
|
US11618776B2
(en)
|
2018-12-20 |
2023-04-04 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
|
|
WO2020148207A1
(en)
|
2019-01-14 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies binding to hla-a2
|
|
JP7542543B2
(ja)
|
2019-01-31 |
2024-08-30 |
サノフィ・バイオテクノロジー |
若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
|
|
EP3930850A1
(en)
|
2019-03-01 |
2022-01-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
SG11202109932WA
(en)
|
2019-03-20 |
2021-10-28 |
Imcheck Therapeutics Sas |
Antibodies having specificity for btn2 and uses thereof
|
|
JP2022545312A
(ja)
|
2019-04-24 |
2022-10-27 |
サノフィ・バイオテクノロジー |
関節リウマチの診断及び処置の方法
|
|
CA3142710A1
(en)
|
2019-06-04 |
2020-12-10 |
Sanofi Biotechnology |
Compositions and methods for treating pain in subjects with rheumatoid arthritis
|
|
WO2021009263A1
(en)
|
2019-07-16 |
2021-01-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity for cd38 and uses thereof
|
|
EP4556488A3
(en)
|
2019-07-18 |
2025-08-13 |
Hanmi Pharm. Co., Ltd. |
Novel method for preparing long-acting drug conjugate through preparation of intermediate
|
|
US12441788B2
(en)
|
2019-09-27 |
2025-10-14 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-müllerian inhibiting substance antibodies and uses thereof
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
BR112022006534A2
(pt)
*
|
2019-10-24 |
2022-07-05 |
Novago Therapeutics Ag |
Anticorpos anti-nogo-a
|
|
WO2021175954A1
(en)
|
2020-03-04 |
2021-09-10 |
Imcheck Therapeutics Sas |
Antibodies having specificity for btnl8 and uses thereof
|
|
EP4149632A1
(en)
|
2020-05-14 |
2023-03-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind msln and cd3
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
GB2595299B
(en)
|
2020-05-21 |
2022-08-03 |
Mabsolve Ltd |
Modified immunoglobulin FC regions
|
|
US11919958B2
(en)
|
2020-08-19 |
2024-03-05 |
Xencor, Inc. |
Anti-CD28 compositions
|
|
CA3198049A1
(en)
|
2020-10-15 |
2022-04-21 |
UCB Biopharma SRL |
Binding molecules that multimerise cd45
|
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
|
KR20230148959A
(ko)
*
|
2022-04-19 |
2023-10-26 |
전남대학교산학협력단 |
플라젤린 및 면역글로불린 Fc 융합 단백질을 포함하는 대장염 치료용 조성물
|
|
KR20230148956A
(ko)
*
|
2022-04-19 |
2023-10-26 |
전남대학교산학협력단 |
플라젤린 및 면역글로불린 Fc 융합 단백질을 포함하는 간 질환 또는 대사증후군 치료용 조성물
|
|
AU2023281650A1
(en)
|
2022-05-30 |
2024-10-17 |
Hanall Biopharma Co., Ltd. |
Anti-fcrn antibody or antigen binding fragment thereof with improved stability
|
|
WO2024115935A1
(en)
|
2022-11-29 |
2024-06-06 |
Inserm |
Methods for the treatment of b-cell lymphoma using cd39 inhibitors
|
|
WO2024146458A1
(zh)
*
|
2023-01-06 |
2024-07-11 |
广东东阳光药业股份有限公司 |
抗il-11细胞因子人源化抗体
|
|
WO2024170543A1
(en)
|
2023-02-14 |
2024-08-22 |
Institut National de la Santé et de la Recherche Médicale |
Anti-cd44 antibodies and uses thereof
|
|
WO2024175760A1
(en)
|
2023-02-24 |
2024-08-29 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of endometriosis
|
|
EP4720125A1
(en)
|
2023-05-30 |
2026-04-08 |
Paragon Therapeutics, Inc. |
Alpha4beta7 integrin antibody compositions and methods of use
|
|
WO2024261239A1
(en)
|
2023-06-23 |
2024-12-26 |
Imcheck Therapeutics |
Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
|
|
EP4762093A1
(en)
|
2023-08-14 |
2026-06-24 |
Paragon Therapeutics, Inc. |
Alpha 4 beta 7 integrin binding proteins and methods of use
|
|
WO2025120015A1
(en)
|
2023-12-06 |
2025-06-12 |
Institut National de la Santé et de la Recherche Médicale |
Cd5 targeting antibodies with depleting and t or b-cell activation effects
|
|
GB202318820D0
(en)
|
2023-12-08 |
2024-01-24 |
UCB Biopharma SRL |
Antibodies
|
|
WO2025162964A1
(en)
|
2024-01-30 |
2025-08-07 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of endometriosis
|
|
WO2026013052A1
(en)
|
2024-07-09 |
2026-01-15 |
Institut National de la Santé et de la Recherche Médicale |
Methods of treating familial adenomatous polyposis
|
|
WO2026039779A1
(en)
|
2024-08-15 |
2026-02-19 |
Yale University |
Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding
|
|
FR3167160A1
(fr)
|
2024-10-08 |
2026-04-10 |
Alga Biologics |
Immunoglobulines avec affinite augmentee pour le fcrn
|
|
WO2026125705A2
(en)
|
2024-12-12 |
2026-06-18 |
Lead Discovery Center Gmbh |
Inhibitory antibodies of cytokine interleukin 11 dependent signaling pathways
|